| Type: | combo |
| Width: | 160px |
| Width2: | 220px |
| Component1: | Medetomidine |
| Class1: | alpha2-adrenoceptor agonist |
| Component2: | Vatinoxan |
| Class2: | alpha2-adrenoceptor antagonist |
| Tradename: | Zenalpha |
| Dailymedid: | Medetomidine and vatinoxan |
| Routes Of Administration: | Intramuscular |
| Atc Prefix: | None |
| Legal Ca: | Rx-only |
| Legal Us: | Rx-only |
| Legal Us Comment: | [1] |
Medetomidine/vatinoxan, sold under the brand name Zenalpha, is a veterinary fixed dose combination medication used as a sedative and analgesic for dogs. It contains medetomidine, an alpha2-adrenoceptor agonist, as the hydrochloride; and vatinoxan, an alpha2-adrenoceptor antagonist, as the hydrochloride.[2]
It was approved for veterinary use in the United States in May 2022, and in Canada in May 2023.[3]